Clinical Schizophrenia & Related Psychoses

Google Scholar citation report

Citations : 6601

Clinical Schizophrenia & Related Psychoses received 6601 citations as per Google Scholar report

Clinical Schizophrenia & Related Psychoses peer review process verified at publons

Indexed In

Citations Report

Clinical Schizophrenia & Related Psychoses : Citations & Metrics Report

Articles published in Clinical Schizophrenia & Related Psychoses have been cited by esteemed scholars and scientists all around the world. Clinical Schizophrenia & Related Psychoses has got h-index 41, which means every article in Clinical Schizophrenia & Related Psychoses has got 41 average citations.

Following are the list of articles that have cited the articles published in Clinical Schizophrenia & Related Psychoses.

	2022	2021	2020	2019	2018
Year wise published articles	105	141	28	8	28
Year wise citations received	543	553	590	563	587

Journal total citations count	6601
Journal Impact Factor	6.49
Journal 5 years Impact Factor	12.17
Journal CiteScore	11.19
Journal h-index	41
Journal h-index since 2016	26

Barnes, Thomas RE, and Schizophrenia Consensus Group of the British Association for Psychopharmacology. "Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology." Journal of Psychopharmacology 25, no. 5 (2011): 567-620. View at Publisher View at Google Scholar View at Indexing
Wu, Mengqian, Nanya Hao, and Dong Zhou. "Spermatorrhea and loss of libido induced by topiramate: first case report and review of literature." Clinical neuropharmacology 39, no. 6 (2016): 325-326. View at Publisher View at Google Scholar View at Indexing
Haddad, Peter M., Cecilia Brain, and Jan Scott. "Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies." Patient related outcome measures 5 (2014): 43. View at Publisher View at Google Scholar View at Indexing
Ochoa, Juan G. "Topiramate improves psychiatric symptoms in a patient with Lewy body dementia." Cognitive and Behavioral Neurology 27, no. 4 (2014): 222-223. View at Publisher View at Google Scholar View at Indexing
Howes, Oliver, Rob McCutcheon, and James Stone. "Glutamate and dopamine in schizophrenia: an update for the 21st century." Journal of psychopharmacology 29, no. 2 (2015): 97-115. View at Publisher View at Google Scholar View at Indexing
Chandradasa, Miyuru, Layani Champika, Silumini de Silva, and K. A. L. A. Kuruppuarachchi. "Topiramate’s effectiveness on weight reduction in overweight/obese persons with schizophrenia: study protocol for a randomized controlled trial." Trials 18, no. 1 (2017): 1-8. View at Publisher View at Google Scholar View at Indexing
Martins-de-Souza, Daniel, Murtada Alsaif, Agnes Ernst, Laura W. Harris, Nancy Aerts, Ilse Lenaerts, Pieter J. Peeters et al. "The application of selective reaction monitoring shows dysregulation of glycolysis in a preclinical model of schizophrenia." (2012). View at Publisher View at Google Scholar View at Indexing
Agarwal, Sri Mahavir, and Ganesan Venkatasubramanian. "Metabolic syndrome in schizophrenia: Theoretical, clinical and translational perspectives." Indian journal of psychological medicine 35, no. 2 (2013): 117. View at Publisher View at Google Scholar View at Indexing
Levin, Jennifer. "Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia." View at Publisher View at Google Scholar View at Indexing
Freudenreich, Oliver. "Clozapine." Psychotic Disorders (2020): 231-248. View at Publisher View at Google Scholar View at Indexing
Kouidrat, Youssef, Ali Amad, and Marc De Hert. "Emerging drugs and indications for cardio-metabolic disorders in people with severe mental illness." Current pharmaceutical design 21, no. 23 (2015): 3317-3324. View at Publisher View at Google Scholar View at Indexing
Mandolini, Gian Mario, Matteo Lazzaretti, Alfredo Carlo Altamura, and Paolo Brambilla. "Substances of Abuse and Hallucinogenic Activity: The Glutamatergic Pathway-Focus on Ketamine." In Hallucinations in Psychoses and Affective Disorders, pp. 33-41. Springer, Cham, 2018. View at Publisher View at Google Scholar View at Indexing
Wegener, Gregers. "Updated Practice Guidelines for the Use of Clozapine in Adult Individuals with Intellectual Disabilities." (2016). View at Publisher View at Google Scholar View at Indexing
Okuyama, Yuji, Kazuto Oya, Shinji Matsunaga, Taro Kishi, and Nakao Iwata. "Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials." Neuropsychiatric disease and treatment 12 (2016): 3221. View at Publisher View at Google Scholar View at Indexing
Krzystanek, Marek, Krzysztof Krysta, Mariusz Borkowski, Katarzyna Ska?acka, Jacek Przyby?o, Artur Pa?asz, Davor Mucic, Ewa Martyniak, and Napoleon Waszkiewicz. "The Effect of Smartphone-Based Cognitive Training on the Functional/Cognitive Markers of Schizophrenia: A One-Year Randomized Study." Journal of Clinical Medicine 9, no. 11 (2020): 3681. View at Publisher View at Google Scholar View at Indexing
Kowalchuk, Chantel, Laura N. Castellani, Araba Chintoh, Gary Remington, Adria Giacca, and Margaret K. Hahn. "Antipsychotics and glucose metabolism: how brain and body collide." American Journal of Physiology-Endocrinology and Metabolism 316, no. 1 (2019): E1-E15. View at Publisher View at Google Scholar View at Indexing
Kane, John M., and Christoph U. Correll. "Benign Ethnic Neutropenia and Clozapine Use." J Clin Psychiatry 77, no. 7 (2016): e909-e916. View at Publisher View at Google Scholar View at Indexing
Lee, Jung Sun, Jun Soo Kwon, Daeho Kim, Sung-Wan Kim, Jae-Jin Kim, Jong-Hoon Kim, Hee Jung Nam et al. "Prevalence of metabolic syndrome in patients with schizophrenia in Korea: a multicenter nationwide cross-sectional study." Psychiatry investigation 14, no. 1 (2017): 44. View at Publisher View at Google Scholar View at Indexing
Reser, Maree. "Investigating factors that influence cognitive response to, and the efficacy of, cognitive remediation therapy in people with schizophrenia." PhD diss., Swinburne University of Technology, 2018. View at Publisher View at Google Scholar View at Indexing
Corriveau, Jennifer A. "Age, Experience, and NMDA Antagonism: Dynamic Regulation of Parvalbumin Expression in Normal and Chronically Ketamine-Treated Rats." (2015). View at Publisher View at Google Scholar View at Indexing
Prev 1 2 ... 23 24 25 26 27 28 29 30 31 32 33 ... 84 85 Next »

Google Scholar citation report

Citations : 6601

Clinical Schizophrenia & Related Psychoses peer review process verified at publons

Indexed In

PMC/PubMed Indexed Articles

Citations Report

Clinical Schizophrenia & Related Psychoses : Citations & Metrics Report

Wu, Mengqian, Nanya Hao, and Dong Zhou. "Spermatorrhea and loss of libido induced by topiramate: first case report and review of literature." Clinical neuropharmacology 39, no. 6 (2016): 325-326.

Haddad, Peter M., Cecilia Brain, and Jan Scott. "Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies." Patient related outcome measures 5 (2014): 43.

Ochoa, Juan G. "Topiramate improves psychiatric symptoms in a patient with Lewy body dementia." Cognitive and Behavioral Neurology 27, no. 4 (2014): 222-223.

Howes, Oliver, Rob McCutcheon, and James Stone. "Glutamate and dopamine in schizophrenia: an update for the 21st century." Journal of psychopharmacology 29, no. 2 (2015): 97-115.

Chandradasa, Miyuru, Layani Champika, Silumini de Silva, and K. A. L. A. Kuruppuarachchi. "Topiramate’s effectiveness on weight reduction in overweight/obese persons with schizophrenia: study protocol for a randomized controlled trial." Trials 18, no. 1 (2017): 1-8.

Martins-de-Souza, Daniel, Murtada Alsaif, Agnes Ernst, Laura W. Harris, Nancy Aerts, Ilse Lenaerts, Pieter J. Peeters et al. "The application of selective reaction monitoring shows dysregulation of glycolysis in a preclinical model of schizophrenia." (2012).

Agarwal, Sri Mahavir, and Ganesan Venkatasubramanian. "Metabolic syndrome in schizophrenia: Theoretical, clinical and translational perspectives." Indian journal of psychological medicine 35, no. 2 (2013): 117.

Levin, Jennifer. "Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia."

Freudenreich, Oliver. "Clozapine." Psychotic Disorders (2020): 231-248.

Kouidrat, Youssef, Ali Amad, and Marc De Hert. "Emerging drugs and indications for cardio-metabolic disorders in people with severe mental illness." Current pharmaceutical design 21, no. 23 (2015): 3317-3324.

Mandolini, Gian Mario, Matteo Lazzaretti, Alfredo Carlo Altamura, and Paolo Brambilla. "Substances of Abuse and Hallucinogenic Activity: The Glutamatergic Pathway-Focus on Ketamine." In Hallucinations in Psychoses and Affective Disorders, pp. 33-41. Springer, Cham, 2018.

Wegener, Gregers. "Updated Practice Guidelines for the Use of Clozapine in Adult Individuals with Intellectual Disabilities." (2016).

Okuyama, Yuji, Kazuto Oya, Shinji Matsunaga, Taro Kishi, and Nakao Iwata. "Efficacy and tolerability of topiramate-augmentation therapy for schizophrenia: a systematic review and meta-analysis of randomized controlled trials." Neuropsychiatric disease and treatment 12 (2016): 3221.

Kowalchuk, Chantel, Laura N. Castellani, Araba Chintoh, Gary Remington, Adria Giacca, and Margaret K. Hahn. "Antipsychotics and glucose metabolism: how brain and body collide." American Journal of Physiology-Endocrinology and Metabolism 316, no. 1 (2019): E1-E15.

Kane, John M., and Christoph U. Correll. "Benign Ethnic Neutropenia and Clozapine Use." J Clin Psychiatry 77, no. 7 (2016): e909-e916.

Lee, Jung Sun, Jun Soo Kwon, Daeho Kim, Sung-Wan Kim, Jae-Jin Kim, Jong-Hoon Kim, Hee Jung Nam et al. "Prevalence of metabolic syndrome in patients with schizophrenia in Korea: a multicenter nationwide cross-sectional study." Psychiatry investigation 14, no. 1 (2017): 44.

Reser, Maree. "Investigating factors that influence cognitive response to, and the efficacy of, cognitive remediation therapy in people with schizophrenia." PhD diss., Swinburne University of Technology, 2018.

Corriveau, Jennifer A. "Age, Experience, and NMDA Antagonism: Dynamic Regulation of Parvalbumin Expression in Normal and Chronically Ketamine-Treated Rats." (2015).